Background: CCL22 played critical roles in Tregs recruitment. The upstream regulators modulating CCL22 in hepatocellular carcinoma (HCC) were not clearly understood. Methods: MiR-23a, p-p65, p65, CCL22, and Foxp3 levels were monitored by RT-qPCR and western blotting. Immunofluorescence assay was used to perform the costaining of Foxp3 and CD4 on liver tissues. Transwell assay was applied to evaluate the migration ability of Tregs. Dual-luciferase assay was performed to determine relationship of miR-23a/CCL22 and p65/miR-23a. Chromatin immunoprecipitation (ChIP) was applied to detect the direct binding of p65 to miR-23a promoter.
| INTRODUCTION
Liver cancer is the fourth most common cancer in China. It was estimated that around 466 thousands of newly diagnosed liver cancer would be reported and caused 422 thousands of death every year in China. 1 On the other hand, it was found that around 80% of liver cancer patients were hepatitis B virus (HBV) carriers in China. 2 This indicates that HBV is a critical risk factor for liver cancer development. Given that a large number of population are infected with HBV in China, researches that aim to decipher HBV-mediated liver cancer development and progression are extremely important.
Increasing evidences demonstrated that immune evasion of tumor cells contributed to cancer progression. 3 Regulatory T cells (Tregs) are a subpopulation of T cells with immunosuppressive capability and have been frequently identified to play critical roles in immune evasion of cancers. 4, 5 A meta-analysis using data from 1279 hepatocellular carcinoma (HCC) patients and 547 healthy controls revealed that the ratio of circulating and tumor-infiltrating Tregs was significantly higher in HCC patients than healthy controls. 6 Meanwhile, high level of Tregs in hepatocellular carcinoma microenvironment represented a poor prognosis with short overall and disease-free survival. 7 More importantly, depletion of Tregs by antibodies or targeting signaling in Tregs was reported to be effective treatments for tumor growth and metastases of hepatocellular carcinoma in the preclinical models. 8, 9 Recently, cancer immunotherapies which target immune checkpoints and recover immune response in tumors were showing great successes in several clinical trials and appeared to be the most promising cancer treatments in future. 10, 11 Based on these findings, targeting the key pathways or molecules that drive intratumoral recruitment of Tregs may hold major potential for clinical application.
C-C Motif Chemokine Ligand 22 (CCL22) is a potent chemoattractant for T-lymphocytes, including Tregs. 12, 13 It was known that tumor cells-derived CCL22 functioned as a key factor for intratumoral recruitment of Tregs in several types of cancers, including liver cancer. 8, 14 Blocking of CCL22 therefore may represent a novel approach for suppression of Tregs recruitment and subsequent tumor growth. 15 Interestingly, bioinformatics analysis predicted that 3'UTR of CCL22 contained a putative-binding site of miR-23a seed sequence. It could be expected that miR-23a-mediated CCL22 degradation might lead to the attenuation of Tregs recruitment into tumor tissues. Interestingly, the tumor suppressive functions of miR-23a have been reported in several types of cancers, including liver cancer. 16, 17 For example, it was reported that berberine-mediated antiproliferation and proapoptosis effects required miR-23a expression in HCC cells. 16 In this respect, investigation of miR-23a and CCL22 relationship may provide a novel strategy for anticancer therapy, yet it has not been studied in HCC.
In order to enhance the feasibility of miR-23a targeting in clinical practice, identification of upstream modulator of miR-23a will be of great interest to researchers. Bioinformatic analysis revealed that there was at least one p65-binding site in the miR-23a promoter, suggesting that p65 could be a modulator of miR-23a expression.
In this study, we hypothesized that there was a p65/ miR-23a/CCL22 axis driving Tregs recruitment in HCC. Inhibition of p65 might induce the expression of miR-23a, which then reduces CCL22 level and attenuates Tregs recruitment in HCC. Given that HBV infection is featured on HCC, the comparisons of miR-23a, p65, and CCL22 expression between HBVand HBV + patients or cell lines were also performed. To our best knowledge, this is the first work that focused on the mechanism of p65/miR-23a/CCL22 axis-mediated Tregs recruitment in HCC.
| MATERIALS AND METHODS

| Human samples
Human tissues were collected and used under a protocol approved by the Ethics Committee of the First Affiliated Hospital of Zhengzhou University (2018-KY-60). The informed consent were signed by all patients. Adjacent normal liver tissues were obtained from 15 patients. Hepatocellular carcinoma (HCC) tissues were obtained from 30 HBV infection negative (HBV − ) and 30 HBV infection positive (HBV + ) cancer patients. For the survival analysis, the longterm follow-up data of HBV + HCC patients (n = 30) and HBV -HCC patients (n = 30) were collected from the First Affiliated Hospital of Zhengzhou University. The tissue samples were immediately frozen in liquid nitrogen till further assays. The clinicopathological features of all HCC patients were shown in Table 1 .
| Cell culture and treatment
The human embryonic hepatocytes cell line WRL68, hepatocellular carcinoma cell line HepG2 (HBV − ) and human embryonic kidney cell line HEK293 were obtained from American Type Culture Collection (ATCC). HepG2.2.15 cells are stablely HBV-transfected cells derived from a hepatoblastoma HepG2 cell line (Chongqing Medical University). All the cells were maintained in Dulbeco's Modified Eagle Medium (DMEM, Gibco) supplemented with 10% of heat-inactivated fetal bovine serum (Gibco) and 1% of Penicillin-Streptomyicin solution (Gibco) in a humidified atmosphere of 5% CO 2 at 37°C. In some experiments, HepG2 or HepG2.2.15 cells were treated with 5 μmol/L parthenolide (a p65 inhibitor, TOCRIS) or miR-23a mimics (GenePharma) for 24 hours. For rescued study, cells were pretreated with miR-23a inhibitor (GenePharma) following by 5 μmol/L parthenolide for 24 hours.
| Immunofluorescence assay
Sections were sliced at a thickness of 5 μm from paraffinembedded tissues blocks, following by deparaffinization and rehydration under a standard protocol. After antigen retrieval with citrate buffer solution (pH 6.0), the sections were treated with 3% hydrogen peroxide in methanol, blocked with 5% goat serum in PBS-T (0.3% Triton X-100 in PBS) for 30 minutes, and incubated with primary antibodies anti-Foxp3 (PA1-46126, ThermoFisher Scientific) and anti-CD4 (MA1-10800, ThermoFisher Scientific) for overnight at 4°C. Fluorescent dye-conjugated secondary antibodies (ThermoFisher Scientific) were then applied to label and visualize the expression of target proteins in tissues.
| Dual-luciferase reporter assay
The reporter assays were performed to investigate the modulation of miR-23a promoter by p65 and CCL22 3′UTR by miR-23a. For promoter assay, miR-23a promoter containing predictive p65-binding site or corresponding mutant promoter was cloned into pGL3-basic vectors. pcDNA3.1-p65 was applied for p65 overexpression. pRL Renilla Luciferase vectors were used as the control plasmid. During transfection process, pGL3:pcDNA3.1-p65:pRL (25:25:1) were cotransfected into HEK293 cells with lipofectamine 3000 (ThermoFisher Scientific) at a ratio of 1:3 (DNA: lipofectamine). As a control, pcDNA3.1 vectors were also applied for cotransfection in the separated experiments as above. After transfection for 48 hours, firefly luciferase activities were determined and adjusted by Renilla luminescence using the kit according to the manufacture's instruction (Promega).
For 3′UTR assay, oligos containing putative miR-23abinding site were cloned from CCL22 3′UTR and inserted into pmirGLO vectors (Promega). The mutant was generated using the Phusion site-directed mutagenesis kit (F541, ThermoFisher Scientific) according to manufacturer's instruction. Briefly, phosphorylated mutagenic primers consisting of mismatch base were designed and applied for linear plasmid amplification using Phusion polymerase. The linear plasmid was then recirculated by T4 ligase and transformed for subsequent manipulation. MiR-23a mimics or scramble control were obtained from GenePharma. pRL vectors were used as the transfection control. During transfection process, miR-23a mimics and pmirGLO vectors were cotransfected into HEK293 cells with lipofectamine 3000 at a ratio of 1:3 (DNA: lipofectamine). After transfection, the luminescence among groups were detected as above.
| Chromatin immunoprecipitation (ChIP) assay
ChIP assay was performed using the ChIP-IT Express Enzymatic kit (Active Motif). The protocol was adopted according to manufacturer's instruction. Anti-p65 (#8242, 1:100) and its isotype IgG control (#3900, 1:100) were obtained from Cell signaling technology. HEK293 cells were cross-linked with formaldehyde, following by enzymatic shearing and antibody incubation for overnight at 4℃. Protein-DNA complex was then immunoprecipitated with protein G magnetic beads. The p65-binding chromatin was eluted, reversed for cross-linking, digested with proteinase K and then purified with the DNA columns. The DNA was then assessed by quantitative PCR.
| Cell sorting
Treg cells were purified from healthy donors using Human Regulatory T cell Sorting Kit according to manufacturer's instructions (BD Pharmingen). Peripheral blood mononuclear cells (PBMC) were isolated from 30 mL whole blood with Ficoll-Paque PREMIUM density gradient media (GE Healthcare Bio-Sciences). This was followed with antibody cocktail staining and flow cytometry sorting. The identification of Treg cells was determined by Foxp3 and CD4/CD25 costaining with flow cytometry. The fraction of CD4 + /CD25 + were collected for subsequent cell migration test.
| Transwell migration assay
The 24-well Transwell culture inserts with 5-μm pore size were applied. Supernatant of HepG2 or HepG2.2.5 cells which were treated with p65 inhibitor/vehicle control or miR-23a mimics/inhibitor/scramble control was seeded onto the lower chamber with 400 μL of culture medium. For p65 inhibitor study, parthenolide, a p65-specific inhibitor, or its vehicle control (DMSO) was treated cells 24 hours before Treg coincubation. For microRNA study, cells were transfected with miR-23a mimics/inhibitor or scramble control 24 hours before coincubation. Purified Treg cells (1 × 10 5 / well) were added to the upper chamber of the transwell and coincubated with conditioned medium for 24 hours at 37°C. For neutralization assay, anti-CCL22 antibody (0.5 μg/mL) or isotype IgG control was also added into the conditioned medium. The migrated Treg cells were counted by researchers who were blinded to the experimental design.
| Stable cell line establishment
pGCMV/EGFP/miR/Blasticidin plasmids containing miR-23a inhibitor sequence or its scramble control were ordered from GenePharma. The plasmids were transfected into HepG2.2.15 cells with Lipofectamine 3000 in a ratio of 1:3 (DNA:Lipofectamine). Monoclonal cell lines that stably express miR-23a inhibitor (HepG2.2.15/miR-23a-inhibitor) or scramble control (HepG2.2.15/NC) were then selected with Blasticidin (10 µg/mL, TOCRIS) and then used to nude mice xenograft study.
| Xenograft tumor model
Six-week-old male BALB/c nude (nu/nu) mice were purchased from Shanghai SLAC Laboratory Animal Center. The nude mice xenograft study was approved by the Animal Ethics Committee in the First Affiliated Hospital of Zhengzhou University. HepG2.2.15 cells which stably express miR-23a inhibitor (HepG2.2.15/miR-23a-inhibitor) or scramble control (HepG2.2.15/NC) were subcutaneously inoculated in the nude mice. In the groups containing p65 inhibitor treatment, 5 mg/kg parthenolide was applied via tail intravenous injection. The xenograft tumor size was measured with a vernier scale for every 5 days. After 30 days, mice were euthanized by cervical dislocation. The tumor tissues were harvested for volume and weight measurement, protein isolation and western blotting analysis.
| RNA isolation and quantitative PCR (qPCR)
Total RNA from human tissues or cell lines was extracted with Trizol reagent (ThermoFisher Scientific) according to the manufacturer's instruction. Complementary DNA (cDNA) was synthesized from 1 μg of total RNA using the PrimeScript RT reagent Kit (Takara). qPCR was performed with SYBR Premix EX Taq TM kit (Takara) in an ABI 7500HT real-time PCR system (Applied Biosystems). GAPDH and U6snRNA were used as an internal control for mRNA and miRNA, respectively. Relative expression levels were calculated by the 2 −ΔΔCq method. 
| Western blotting
| Statistical analysis
All the experiments were performed for three times, data were expressed as mean ± standard deviation (SD). Statistical analyses were performed by GraphPad Prism 6 (GraphPad Software, Inc). Unpaired two-tailed t test was used for comparison between two groups. One-way analysis of variance (ANOVA) followed by Tukey post hoc test was used for multiple comparison. The Kaplan-Meier estimate was applied to compare the overall survival time between HBV + and HBV − cancer patients. The correlation between HBV + and HBV − cancer patients and clinicopathological characteristics of patients was assessed by the Chi-squared test. The significance of difference was determined as indicated in the figure legends. *P < .05 was considered significant.
| RESULTS
| Lower miR-23a expression was correlated with higher level of CCL22 expression and intratumoral Treg recruitment in HBV-positive HCC
To investigate the roles of potential Tregs modulators, we explored whether the expression levels of miR-23a, CCL22, and Foxp3 were associated with the progression of patients. First, the long-term follow-up was conducted for up to 3000 days after hospital discharge. As presented in the Figure  1A , HBV infection significantly reduced the overall survival time of cancer patients than noncarriers. As shown in Table  1 , HBV infection was associated with distant metastasis (P < .05). This indicated that HBV could be a critical factor of tumor progression. To explore the mechanism of HBVrelated tumor development, miR-23a was investigated in this study. Consistent with previous reports in other tumors, it was found that miR-23a level was significantly lower in both types of tumors (HBV − and HBV + ) than in normal controls. Notably, significant difference in miR-23a was also observed between HBV + and HBV − tumors, HBV infection appeared to further reduce the expression of miR-23a ( Figure 1B ). This observation indicated that miR-23a might play a role in HBV-mediated tumor progression. Of note, CCL22, a key gene mediates Tregs recruitment and tumor immune evasion, was found in the candidate list. As expected, both CCL22 and Foxp3 (marker of Tregs) mRNA levels were increased in tumor samples when compared with in adjacent normal tissues ( Figure 1C,D) . Importantly, HBV infection was associated with higher levels of CCL22 and Foxp3 than no HBV infection ( Figure 1C,D) , indicating more Tregs (Foxp3 positive) were recruited into the tumor tissues of HBV carriers than noncarriers. The results of CCL22 and Foxp3 protein levels ( Figure 1E ,F) in each group were consistent with the mRNA results in Figure 1C ,D. Next, we examined whether p65, one of the most important transcription regulators in the tumor progression, was involved in the dysregulation of these genes. As shown in Figure 1E ,F, p-p65 and total p65 levels were significantly induced in HBV + and HBV − tumors, and HBV + tumors contained the highest level and normal tissues had lowest level. The pattern of alterations was similar with CCL22 and Foxp3, indicating that p65 might be involved in the regulation of these molecules. Furthermore, the costaining of Foxp3 and CD4 (markers of T cells) were evaluated by immunofluorescent staining in tissues ( Figure 1G ). The results indicated the CD4 + Foxp3 + cells were significantly increased in both types of tumors (HBV − and HBV + ) than in normal controls, and HBV infection appeared to more CD4 + Foxp3 + cells. These data implied that the alterations in Foxp3 levels (mRNA and protein) were mostly due to changes in Tregs population in tumor tissues. To explore whether functional interactions existed between these dysregulated molecules, the correlation between miR-23a and CCL22 or Foxp3 was then computed in three types of tissue samples. It was shown that no significant correlation could be observed between miR-23a expression and CCL22 or Foxp3 expression in normal group. But, a significant inverse correlation between miR-23a and CCL22 or Foxp3 was found from HBVtumor group and HBV + tumor group ( Figure 1H ,I).
| MiR-23a, p-p65, p65, and CCL22 levels were dysregulated in HCC cell lines
Next, the dysregulation of above genes was validated in normal liver cell line and HCC cell lines. In consistent with tissue samples, similar changes in gene expression were also observed among WRL68, HepG2 (HBV − ) and HepG2.2.15 (HBV + ) cells. Lower level of miR-23a was observed in HepG2 and HepG2.2.15 cells than WRL68 cells ( Figure  2A ), whereas CCL22 mRNA ( Figure 2B ) and protein levels ( Figure 2C,D) were increased in HCC cells. Similarly, both p-p65 and p65 protein level were upregulated in HepG2 and HepG2.2.15 cells ( Figure 2C,D) . But, there was no significant difference in the ratio of p-p65/p65 among three cell lines ( Figure 2D ). In particular, it was worth to note that HBV infection appeared to be sufficient to downregulate miR-23a and increase CCL22 and p65 expression, as indicated by the comparison between HepG2.2.15 and their parental cells HepG2. Meanwhile, the results also implied that these cell lines would be good models for the studies of HBV-mediated tumor progression. HepG2 and HepG2.2.15 were therefore chose for subsequent functional studies.
| p65 promoted Tregs recruitment via directly modulating miR-23a
As demonstrated in Figure 1 , p65 expression was inversely correlated with miR-23a expression ( Figure 1) . To explore the potential interaction of p65 and miR-23a, we examined whether p65 could act as a transcriptional repressor of miR-23a in liver cancer. Promoter analysis revealed that a consensus p65-binding sequence (AGGGATTTCC) was located in the promoter region of miR-23a. The promoter region containing wide type (WT) or mutated (Mut, AGAGGGTCTAC) | 717 LI et aL.
p65-binding site was then subcloned into pGL3-basic vector ( Figure 3A ). Dual-luciferase assay showed that p65-binding site mutagenesis did not affect the basal activity of promoter ( Figure 3B ). However, p65 overexpression significantly reduced the wide type of miR-23a promoter driven luciferase expression, but not its mutant counterpart ( Figure 3B ). Furthermore, ChIP assay showed that the promoter region of miR-23a could be significantly enriched by anti-p65 but not its isotype IgG control ( Figure 3C ). These results indicated that induction of p65 expression was sufficient to repress miR-23a promoter activity. Treatment with parthenolide, a p65-specific inhibitor, disinhibited the expression of miR-23a ( Figure 3D ), whereas significantly decreased phosphorylated form of p65 and CCL22 protein and mRNA levels in both tumor cell lines (Figure 3E-G) . Moreover, purified Tregs ( Figure 3H) were applied in the transwell migration assay. It should be noted that significantly more Tregs were recruited by HepG2.2.15 cells than HepG2 cells. p65 inhibition by parthenolide treatment greatly attenuated Tregs migration in both HepG2 and HepG2.2.15 cell lines ( Figure  3I ). We concluded that p65 promoted Tregs recruitment via directly modulating miR-23a.
| MiR-23a inhibited Tregs recruitment via directly targeting CCL22
Next, we studied whether miR-23a was involved in the CCL22 expression to modulate Tregs recruitment. As mentioned above, CCL22 3′UTR was predicted to contain a 7 bp seedbinding sequence for miR-23a ( Figure 4A ). This region and its mutated counterpart were therefore subcloned into pmirGLO vector and applied for luciferase assay. Cotransfection study revealed that miR-23a mimics destroyed wide type but not mutated 3′UTR activity of CCL22 ( Figure 4B ). qPCR assay confirmed that miR-23a mimics transfection significantly increased miR-23a level in both cell lines ( Figure 4C ). While neither p-p65 nor p65 was altered, miR-23a mimics did dramatically reduce CCL22 protein and mRNA levels ( Figure  4D-F) . As a consequence, miR-23a mimics also remarkably attenuated Treg cell transmigration ( Figure 4G) . These results confirmed that CCL22 was a target gene of miR-23a. It should be noted that neither p65 phosphorylation nor total p65 level responded to miR-23a mimics. Instead, p65
inhibition could lead to significant upregulation of miR-23a expression ( Figure 3) . These results suggested that p65 was an upstream repressor of miR-23a, which may directly target to CCL22 and further modulate Tregs recruitment.
| MiR-23a inhibitor reversed p65 inhibition effects on CCL22 and Tregs recruitment
Given that p65 modulated miR-23a expression, and that CCL22 was a direct target of miR-23a, it was speculated that the p65/miR-23a/CCL22 axis was existed in the liver cancer cells. To this end, cotreatment with p65 inhibitor and miR-23a inhibitor was applied to the HepG2 and HepG2.2.15 cells. As indicated by the qPCR results, parthenolide significantly upregulated miR-23a level compared to vehicle control, whereas cotreatment with miR-23a inhibitor efficiently reversed this action ( Figure  5A ). Western blotting assay showed that parthenolide alone significantly inhibited the protein levels of p-p65 and p65 and decreased both protein and mRNA levels of CCL22 ( Figure 5B-D) . However, pretreatment with miR-23a inhibitor caused no effects on p-p65 and p65 but abolished the repressive effects on CCL22 induced by parthenolide ( Figure 5B-D) . These results suggested p65 inhibition reduced CCL22 expression through inducing miR-23a expression. Finally, consistent changes were also observed in the transmigration assay using Treg cells. MiR-23a inhibitor treatment alone induced Tregs recruitment. While p65 inhibition significantly reduced Tregs recruitment, pretreatment with miR-23a inhibitor completely abolished such actions ( Figure 5E ). Moreover, when coadministrated with anti-CCL22 neutralizing antibody, the promoting effects of miR-23a inhibitor on Tregs recruitment were significantly diminished ( Figure 5F ). Our findings provided evidence that p65-induced CCL22 induction was mediated by transcriptionally repressing miR-23a, and that CCL22 was the indispensable effector underlying p65/miR-23a axis and Tregs recruitment. It was deduced that the axis of p65/miR-23a/CCL22 was presented in the hepatocellular carcinoma cells and might drive the tumor progression by recruiting Tregs, particularly when HBV infection was involved. 
| MiR-23a inhibitor reversed p65 inhibition effects on HBV-positive xenograft tumor growth
The roles of p65/miR-23a/CCL22 axis was then investigated in the xenograft tumor models. The mice were assigned into five groups according to the treatment. It was shown that p65 inhibitor treatment significantly retarded tumor growth and miR-23a inhibitor promoted tumor growth as indicated by the tumor weight and size ( Figure 6A-C) . In addition, the therapeutic effects induced by p65 inhibitor were dramatically impaired through cotreatment with miR-23a inhibitor ( Figure  6A-C) . This finding coincided with in vitro studies and further strengthened the idea that miR-23a was the downstream effector of p65 during tumor progression. More importantly, the protein and mRNA levels of CCL22 in the xenograft tumors was highly analogous to the situation of tumor size among groups ( Figure 6D-F) . Altogether, we concluded that p65 overactivation could repress miR-23a expression, leading to CCL22 disinhibition and subsequent promote tumor growth. Targeting the p65/miR-23a/CCL2 axis represents a novel approach for HBV-positive HCC therapy. 
| DISCUSSION
Around 80% liver cancer patients are HBV carriers in China. 2 Chronic hepatitis B may develop liver fibrosis, cirrhosis, and HCC eventually. 18 Although HBV has been identified as a highly tumorigenic factor, the HBV-featured molecule events for the HCC progression are not clearly understood.
One possible reason is that comparison between HBVand HBV + liver cancer is lack. In this study, we demonstrated that dysregulation of p65/miR-23a/CCL22 axis contributed to Tregs recruitment and hepatocellular carcinoma growth. We further showed that HBV infection aggravated the malignancy by enlarging the dysregulation of such axis. Meta-analysis revealed that elevation of tumor-infiltrating Tregs predicted poor prognosis of hepatocellular carcinoma. 6, 8 We found that intratumoral Foxp3 expression was significantly upregulated in HBV + patients in comparison with both healthy control and HBV − patients. Also, the CD4 + Foxp3 + cells were significantly increased in HBV + patients ( Figure 1 ). But, in consideration of the complexity of the tissues, especially in HCC tissues, combined our qPCR and western blotting results in Figure 1C -F, all these results could suggest that more Tregs were recruited into HBV + tumor tissues. Our observation therefore may highlight intratumoral Tregs as risk factors for poor prognosis and explain the survival analysis which showed that HBV infection caused significant shorter survival time than HBV negative. This was consistent with previous reports showing that Tregs invasion was gradually increased in different stages of tumorigenesis of HCC, from HBV infection, cirrhosis, adenomatous hyperplasia, primary HCC to advance HCC. 19 Tumor cells-derived CCL22 was a critical chemoattractant for Tregs recruitment. 8, 14 In this study, we demonstrated that Foxp3 level was associated with the expression of CCL22. Higher Foxp3 in HBV + tumors were accompanied to higher CCL22 level when compared with HBVtumors ( Figure 1 ). Consistently, the expression level of CCL22 was higher in HepG2.2.15 cells (HBV + ) than HepG2 (HBV − ) and WRL68 (normal) cells. Given that CCL22 acted as an essential attractive signal of Tregs recruitment in various cancers, 14, 20, 21 and that Foxp3 was the highly specific marker of Tregs, higher CCL22 and Foxp3 levels in HBV + tumor implied higher intratumoral Tregs infiltration than HBVtumors. In contrast, miR-23a expression was found to be inversely correlated F I G U R E 6 MiR-23a inhibitor reversed p65 inhibition effects on HBV-positive xenograft tumor growth. A, Xenografted tumors were harvested after different treatments. B and C, p65 inhibitor treatment significantly retarded tumor growth and miR-23a inhibitor promoted tumor growth as indicated by the tumor weight and size. The therapeutic effects of p65 inhibitor were abolished by cotreatment with miR-23a inhibitor. D, CCL22 protein levels from each group were detected by western blotting. E, Statistical results in D. p65 inhibitor led to reduction of CCL22 protein level but miR-23a inhibitor increased CCL22 level in tumor tissues. F, p65 inhibitor led to reduction of CCL22 mRNA level but miR-23a inhibitor increased CCL22 mRNA level in tumor tissues. MiR-23a inhibitor reversed p65 inhibition effects on CCL22 level in tumor tissues. Error bars represented mean ± SD. *P < .05 and **P < .01 with both CCL22 and Foxp3, particularly in HBV + tumors (Figure 1) . Similarly, it was found that miR-23a level was significantly lower in both types of tumors (HBV-and HBV+) than in normal controls ( Figure 2 ). Silico analysis revealed that CCL22 3′UTR contained a binding site of miR-23a seed sequence. Transfection with miR-23a mimics dramatically blocked 3′UTR activity. Moreover, miR-23a mimics efficiently reduced CCL22 expression in both protein and mRNA levels, and attenuated CCL22-dependent Tregs recruitment ( Figure 4 ). Our study, for the first time, identified miR-23a as an upstream repressor of CCL22 and Tregs recruitment. Taken together with the functional study and the observation that miR-23a was significantly lower in tumor tissues than healthy control, we concluded miR-23a could be a novel tumor suppressor in HCC. This was consistent with the reports that miR-23a could suppress proliferation of pancreatic cancer cells 22 and prostate cancer cells. 23 Notably, differential expression of miR-23a was also observed between HBV + and HBVtumors ( Figure 1) . The presence of HBV caused even lower miR-23a expression. Our finding therefore suggested that different clinical outcome between HBV + and HBV − patients was, at least in part, due to the differential miR-23a reduction.
Despite that a number of microRNAs were shown to hold antitumor potential, the clinical application remains a great challenge. Alternatively, upstream modulators of these microRNAs would be options for the future application. In this study, we demonstrated that p65 was a strong transcriptional repressor of miR-23a. Inhibition of overactivated p65 could be a promising approach for the recovery of miR-23a in HCC. In human tissues, phosphorylated and total p65 levels were higher in tumors than normal controls. In cell lines, total p65, and to a less extent, phosphorylated p65 were significantly increased in HepG2 and HepG2.2.15 than WRL68. These results demonstrated that total p65 level was inversely correlated with miR-23a expression. Dual-luciferase and ChIP assays revealed that the p65-binding site in the promoter region of miR-23a was accessible for p65 ( Figure 3 ). Moreover, Parthenolide, a p65 inhibitor, could reduce CCL22 expression, disinhibit miR-23a expression and inhibit Tregs migration in vitro (Figure 3) . These findings suggested that elevation of p65 was sufficient to repress miR-23a expression and hence release the brakes on tumorigenesis by miR-23a. Although phosphorylation has been highlighted to play important roles in the molecular function of p65, it is not always the case. For example, p65 directly bound to the promoter region of miR-590 and repressed its expression in osteosarcoma, a process independent of p65 phosphorylation. 24 Alternatively, p65 might act like a scaffold protein and recruit HDAC to miR-23a promoter, which in turn inhibited the expression of miR-23a in leukemic Jurkat cells. 25 We concluded that phosphorylation was not indispensable to p65-mediated inhibition of miR-23a expression in HCC. Previously, it has been frequently reported that overactivated p65 signaling pathway was intensively involved in the tumorigenesis of HCC via directly promoting the cell survival and proliferation. 26, 27 Our study therefore proposed a novel mechanism that p65 may facilitate HCC progression via Tregs recruitment.
On the other hand, pretreatment with miR-23a inhibitor abolished these effects induced by p65 inhibitor, which resulted in reversing the expression of miR-23a and CCL22 and increasing Tregs recruitment. It also should be noted that Tregs recruitment by miR-23a inhibition was reversed by CCL22 neutralizing antibody pretreatment ( Figure 5 ). This result strengthened that CCL22 was the downstream effector of p65/miR-23a axis and Tregs recruitment. Previously, it was demonstrated that upregulated CCL22 was essential for Tregs recruitment and venous metastases of HBV + HCC. 8 Furthermore, TGF-β/miR-34a axis was identified to play a crucial role in the expression of CCL22. 8 Our study provided a novel mechanism underlying CCL22 modulation by revealing the role of p65/miR-23a axis. Also, in tumor tissues, HBV infection appeared to cause more dramatical changes in gene expression of p65, miR-23a and CCL22 than no infection. In particular, the animal study using HepG2.2.15 cells (HBV + ) suggested that blockage of p65 may efficiently attenuate tumor-infiltrating Tregs and consequent tumor growth through miR-23a induction ( Figure 6 ).
| CONCLUSIONS
Our findings provided strong evidences that p65 functioned as an upstream modulator of miR-23a. Blockage of p65 was sufficient to recover miR-23a expression in tumor cells, which then repressed CCL22 expression and Tregs recruitment into tumor tissues. To the best of our knowledge, this is the first study to identify the p65/miR-23a/ CCL22 axis as a novel molecular mechanism that could drive intratumoral Tregs recruitment and tumor progression. Our study therefore suggested that targeting p65/ miR-23a/CCL22 axis was a potential approach for the control of HBV + HCC progression.
